(TNYA) Tenaya Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TNYA) Tenaya Therapeutics, Inc. Complete Analysis Pack
Tenaya Therapeutics Business Model Canvas: Growth Strategy at a Glance
Discover how Tenaya Therapeutics, Inc. turns cutting-edge gene therapy research into a focused business model built for long-term growth. This full Business Model Canvas breaks down its value proposition, partnerships, customer segments, and cost structure in a clear, practical format. Perfect for investors, analysts, and strategists who want the complete picture—download the full version today.
Partnerships
AAV CDMOs
Tenaya uses AAV CDMOs to make GMP-grade vectors for TN-201, TN-401, and DWORF, which all need specialized production and release testing. Outsourcing this work cuts the need for heavy plant capex and helps the company move 3 gene therapy programs faster.
Cardiology trial sites
Specialty hospitals and heart centers are Tenaya Therapeutics, Inc.'s key access point for rare cardiomyopathy and heart failure patients, especially in gHCM, gARVC, gDCM, and HFpEF trials. They also drive the clinical safety and efficacy data needed to move programs forward, and HFpEF alone accounts for about half of all heart failure cases.
Genetic testing labs
Genetic testing labs help Tenaya Therapeutics identify MYBPC3 and PKP2 mutation carriers for precision enrollment, which is critical in rare-disease trials where each eligible patient matters. External labs also support genotyping, biomarker work, and patient matching, helping speed screening and improve trial efficiency when patient pools are small.
CRO and data vendors
Tenaya Therapeutics, Inc. leans on CROs and data vendors to run multi-site cardiovascular trials, covering monitoring, biostatistics, and day-to-day trial ops. Imaging cores and endpoint-adjudication partners are especially important in heart studies, where blinded review helps keep results clean across sites.
- CROs manage sites and data
- Imaging supports cardiac endpoints
- Adjudication improves trial quality
These partners cut execution risk and speed readouts in early and mid-stage studies.
Academic cardiology experts
Academic cardiology experts are a core partner for Tenaya Therapeutics, Inc. because key opinion leaders help shape translational science, refine program design, and add publication credibility in rare cardiovascular disease. Their hospital and research networks also support faster patient recruitment and independent scientific validation for early-stage gene therapy work.
- Guides translational study design
- Adds peer-reviewed credibility
- Helps recruit rare-disease patients
- Supports scientific validation
Tenaya’s Gene Therapy Pipeline Runs on Critical Partners
Tenaya Therapeutics, Inc. depends on AAV CDMOs, CROs, specialty heart centers, genetic labs, and academic KOLs to advance its 3 gene therapy programs, cut capex, and speed rare-patient enrollment. These partners are central to GMP vector supply, trial execution, and blinded cardiac endpoint review.
| Partner | Why it matters |
|---|---|
| CDMOs | GMP AAV supply |
| Heart centers | Rare-patient access |
| CROs | Multi-site trial ops |
| KOLs | Study design credibility |
What is included in the product
Detailed Word Document
A concise Business Model Canvas summarizing Tenaya Therapeutics’ gene therapy strategy, partnerships, and value creation across the 9 core blocks.
Customizable Excel Spreadsheet
Condenses Tenaya Therapeutics’ business model into a quick, editable snapshot to spot pain points fast.
Reference Sources
Tenaya Therapeutics, Inc. Reference Sources provide a credible audit trail that speeds due diligence and supports faster, better-informed decisions.
Activities
AAV and small-molecule discovery
Tenaya Therapeutics, Inc. runs a 5-program cardiovascular discovery engine: TN-201, TN-401, TN-301, DWORF, and the Reprogramming program. Its AAV and small-molecule work links disease biology to therapy design, aiming to move precision gene and drug candidates from target validation into the clinic.
Preclinical cardiac research
In 2025, Tenaya Therapeutics, Inc. kept testing its cardiac candidates in disease models before human studies, using the readouts to judge efficacy, biodistribution, and safety. This preclinical work is core to its rare disease and regeneration programs, where the goal is to show the therapy reaches heart tissue and works as planned.
Clinical trial execution
Tenaya Therapeutics runs early clinical development across its lead programs, with site management and patient follow-up driving data from patients in genetic cardiomyopathy and heart failure. Its MYPEAK studies are built to read out human safety and efficacy signals early, using enrolled patient cohorts to guide dose, biomarker, and progression decisions.
CMC and regulatory operations
Tenaya Therapeutics, Inc. runs CMC work across its gene therapy and small-molecule pipeline to keep drug substance, release testing, and scale-up ready for clinic use. Regulatory ops then support INDs, amendments, and trial updates; in 2025, this mattered across 3 active programs, helping keep assets development-ready.
- CMC = manufacturing and quality control
- Regulatory work keeps trials moving
- Supports INDs and protocol changes
Genetic patient identification
Tenaya Therapeutics, Inc. uses genetic patient identification to find mutation-defined groups, with MYBPC3, PKP2, and other markers driving enrollment for precision medicine trials. This matters because rare inherited cardiomyopathy programs need tight screening to match the right patients to the right gene-targeted therapy.
- Targets mutation-defined populations
- Uses MYBPC3 and PKP2 markers
- Supports precision medicine enrollment
Tenaya Advances Three Programs with Preclinical, CMC, and Clinical Momentum
In 2025, Tenaya Therapeutics, Inc. focused on preclinical testing, CMC scale-up, and regulatory work to move its 3 active programs into and through the clinic. It also ran patient finding, site management, and follow-up for mutation-defined trials, using safety, biodistribution, and biomarker data to steer dose and progression choices.
| Key activity | 2025 focus |
|---|---|
| R&D and preclinical | 3 active programs |
| Clinical ops | Patient follow-up and site management |
| CMC and regulatory | INDs, release testing, scale-up |
Delivered as Displayed
Business Model Canvas
The Tenaya Therapeutics, Inc. Business Model Canvas preview shown here is the exact same document you’ll receive after purchase. It’s not a sample or mockup—what you see is a direct view of the final file. Once your order is complete, you’ll get full access to this same professionally formatted document.
Resources
TN-201 TN-301 TN-401 pipeline
TN-201, TN-301, and TN-401 are Tenaya Therapeutics, Inc.'s core clinical and preclinical assets. TN-201 targets gHCM, TN-301 targets HFpEF and gDCM, and TN-401 targets gARVC; as of the latest public pipeline update, these programs remain the main economic resource behind the platform.
AAV and regeneration platforms
Tenaya Therapeutics, Inc. uses two core platforms: AAV gene therapy and cardiac regeneration, backed by delivery and cardiac biology know-how. The mix of AAV, small molecules, and cell-based regeneration gives the company multiple shots on goal across genetic cardiomyopathy and heart failure targets.
MYBPC3 and PKP2 know-how
Tenaya Therapeutics, Inc.’s MYBPC3 and PKP2 know-how is a core asset for gene-led target selection and tighter trial enrollment in rare cardiomyopathies. MYBPC3 haploinsufficiency drives a large share of inherited hypertrophic cardiomyopathy, and PKP2 is a leading cause of arrhythmogenic cardiomyopathy, which affects about 1 in 2,000 to 1 in 5,000 people.
Intellectual property portfolio
Tenaya Therapeutics, Inc. relies on its intellectual property portfolio of patents and proprietary know-how to protect candidate designs and platform methods, which is vital in gene therapy and precision medicine where exclusivity drives value. This IP also strengthens future partnering and commercialization leverage.
- Protects candidate and platform designs
- Supports gene therapy exclusivity
- Improves partnering leverage
South San Francisco team
Tenaya Therapeutics, Inc. is based in South San Francisco, California, and its scientific and development staff drive research, clinical, and regulatory work from that hub. In biotech, human capital is the core asset: Tenaya had about 140 employees at year-end 2024, and that talent base is what turns lab work into INDs, trial data, and FDA-ready filings.
- South San Francisco headquarters
- About 140 employees in 2024
- Scientific, clinical, regulatory execution
Tenaya’s Core Assets Power Its Gene Therapy Edge
Tenaya Therapeutics, Inc.’s key resources are its TN-201, TN-301, and TN-401 programs, plus its AAV gene therapy and cardiac regeneration platforms. These assets are supported by MYBPC3 and PKP2 disease know-how, which helps target rare inherited cardiomyopathies and sharpen trial design.
Its patent portfolio and South San Francisco team turn that science into IND work, clinical execution, and partner value.
| Key resource | Latest known fact |
|---|---|
| Employees | ~140 at year-end 2024 |
| Core assets | TN-201, TN-301, TN-401 |
| Platforms | AAV gene therapy, cardiac regeneration |
Value Propositions
Mutation-targeted heart therapies
Tenaya Therapeutics is building mutation-targeted heart therapies for genetically defined cardiovascular disease, with lead focus on MYBPC3- and PKP2-driven disorders. This precision model treats the root cause instead of only symptoms; hypertrophic cardiomyopathy affects about 1 in 500 people, showing the scale of unmet need.
AAV gene therapy for cardiomyopathy
Tenaya Therapeutics’ value proposition is AAV gene therapy for cardiomyopathy: TN-201, TN-401, and DWORF aim to deliver direct gene replacement or correction in heart cells, targeting the root causes of rare cardiomyopathies. As of 2025, the platform spans 3 AAV programs and includes clinical-stage work in MYBPC3- and PKP2-linked disease.
TN-301 for HFpEF and gDCM
TN-301 is Tenaya Therapeutics, Inc.'s small-molecule HDAC6 inhibitor for HFpEF and genetic dilated cardiomyopathy, giving the pipeline a non-gene-therapy angle. HFpEF affects about 6.7 million U.S. adults, and dilated cardiomyopathy is a major cause of heart failure, so TN-301 targets a large unmet need with a broader, more flexible platform.
Cardiac regeneration approach
Tenaya Therapeutics, Inc.’s Reprogramming program targets cardiac regeneration by replenishing heart cells lost after myocardial infarction, not just easing symptoms. That matters in heart failure, which affects about 6.7 million U.S. adults and over 60 million people worldwide, where lost cardiomyocytes do not naturally recover.
- Replaces lost heart cells after MI
- Targets root cause, not symptoms
- Addresses a major HF unmet need
Precision medicine in rare disease
Tenaya Therapeutics, Inc. links genetics, biomarkers, and cardiac biology to better match patients to the right therapy, which matters in rare disease where the wrong fit can blur results. In 2025, Tenaya Therapeutics, Inc. said TN-201 Phase 1b/2 data showed dose-dependent MYBPC3 protein restoration and biomarker shifts, helping support clearer endpoints in a small patient pool.
- Genetics + biomarkers sharpen selection
- Cardiac biology improves treatment fit
- Rare disease can tighten endpoints
Tenaya’s Precision Heart Therapies Target Disease at Its Source
Tenaya Therapeutics, Inc. offers mutation-matched heart therapies that aim to fix the cause of disease, not just slow symptoms, across MYBPC3, PKP2, and HFpEF-linked programs. Its mix of AAV gene therapy, a small-molecule HDAC6 inhibitor, and cardiac regeneration gives it reach across rare inherited cardiomyopathies and larger heart-failure markets.
| Program | Value |
|---|---|
| TN-201 | MYBPC3 gene replacement |
| TN-401 | PKP2 arrhythmogenic cardiomyopathy |
| TN-301 | HFpEF, dilated cardiomyopathy |
Customer Relationships
Physician investigator collaboration
Tenaya Therapeutics, Inc. relies on cardiologists and trial investigators to run its rare-disease studies, where endpoints, dosing, and patient selection need deep clinical judgment. These ties are highly technical and science-led, and they also help Tenaya read small-data signals from its 2025 cardiomyopathy and gene-therapy programs.
Clinical trial participant engagement
Tenaya Therapeutics, Inc. relies on informed consent and site-based follow-up to keep clinical trial participants engaged, especially in gene therapy and cardiomyopathy studies that often need months to years of monitoring. Trust and retention matter because these trials track safety, cardiac function, and durability over long observation periods, so missing visits can weaken the data set.
Key opinion leader network
Tenaya Therapeutics, Inc. relies on cardiomyopathy and heart failure key opinion leaders to shape its 2 lead clinical programs, TN-201 and TN-401. Their input guides trial design, endpoint selection, and publication plans, which strengthens medical credibility and helps the Company stay aligned with real-world practice.
Investor communication
Tenaya Therapeutics, Inc. keeps a live investor line through earnings calls, SEC filings, and pipeline updates, which matters because the Company is still funding clinical and preclinical work as a public biotech. That communication helps support access to capital, especially when future R&D spend and financing needs stay high.
- Regular pipeline updates
- Financing visibility for shareholders
- Supports continued funding
Rare disease community ties
Tenaya Therapeutics, Inc. leans on rare disease community ties because patient advocacy groups and genetic disease networks speed awareness, education, and trial recruitment in rare cardiology. With rare diseases affecting about 300 million people worldwide across roughly 7,000 conditions, these ties help Tenaya Therapeutics, Inc. build longer-term engagement around each indication.
Advocacy groups boost awareness and trust.
Community ties help recruit for trials faster.
Engagement can last across each indication.
Tenaya’s Trial Relationships Drive TN-201 and TN-401 Progress
Tenaya Therapeutics, Inc. builds customer ties through cardiologists, rare-disease key opinion leaders, and trial sites around TN-201 and TN-401. In 2025, that model depended on long follow-up, informed consent, and site retention to keep safety and efficacy data intact.
| Relationship | Why it matters | 2025 focus |
|---|---|---|
| KOLs and sites | Trial design and recruitment | TN-201, TN-401 |
Channels
Hospital trial sites
Tenaya Therapeutics, Inc. uses specialized cardiology trial sites to reach patients in its lead gene therapy studies, with screening, dosing, and follow-up run at these centers. This is its key near-term development channel: the company reported $62.0 million in cash, cash equivalents, and short-term investments at March 31, 2025, underscoring its reliance on efficient site activation and enrollment.
Genetic referral networks
Genetic referral networks are key for Tenaya Therapeutics because patients are found through mutation testing and cardiology specialist referrals, which is vital for rare MYBPC3 and PKP2 disease programs. HCM affects about 1 in 500 people, while PKP2-linked arrhythmogenic cardiomyopathy is far rarer, so this channel helps reach the small eligible pool faster.
Scientific congresses
Scientific congresses let Tenaya Therapeutics, Inc. present fresh cardiology data to experts at meetings like ACC and AHA, which helps rare-disease visibility and keeps investigators engaged. Publications do the same job in peer review, giving the company a durable record as it advances its heart-focused pipeline.
Investor relations site
Tenaya Therapeutics, Inc. uses its investor relations site to post SEC filings, earnings materials, and pipeline updates, so investors can track clinical progress and funding needs online. For a public biotech, this channel is standard and helps build market awareness, support fundraising, and keep the stock story current.
- SEC filings and press releases
- Clinical pipeline and trial updates
- Supports investor reach and capital access
Future specialty commercialization
If approved, Tenaya Therapeutics, Inc.'s therapies would likely move through specialty distribution and cardiology specialist prescribers, with controlled access common for gene therapy. This channel is not yet revenue generating; Tenaya reported $0 product revenue and $115.7 million in cash, cash equivalents, and short-term investments as of Dec. 31, 2025.
- Specialty distribution
- Specialist prescribers
- Controlled access model
- No revenue yet
Tenaya’s Rare-Disease Reach Hinges on Fast Site Activation
Tenaya Therapeutics, Inc. reaches patients through specialist cardiology trial sites, genetic referral networks, and conference/publication channels that support rare-disease enrollment and investigator interest. As of Dec. 31, 2025, the Company held $115.7 million in cash, cash equivalents, and short-term investments, so efficient site activation still matters.
| Channel | Role | 2025 data |
|---|---|---|
| Trial sites | Enrollment and follow-up | $115.7M cash |
| Referrals | Rare-patient reach | No product revenue |
Customer Segments
gHCM patients
TN-201 is aimed at gHCM patients with MYBPC3 haploinsufficiency, a rare, mutation-defined subgroup inside hypertrophic cardiomyopathy, which affects about 1 in 500 adults. Tenaya Therapeutics, Inc. is targeting a small, genetically confirmed segment where the unmet need is high and the patient pool is narrow.
gARVC patients
gARVC patients are a genetically defined segment with arrhythmogenic right ventricular cardiomyopathy, and TN-401 is built for PKP2-related disease. ARVC affects about 1 in 2,000 to 1 in 5,000 people, and PKP2 variants are the most common cause in inherited cases, so this group is small but clearly defined.
gDCM patients
gDCM patients are a core target because dilated cardiomyopathy affects about 1 in 2,500 people, and roughly 20% to 35% of cases have a genetic cause. Tenaya Therapeutics, Inc. is aiming at this group with DWORF and TN-301, both built around DCM biology; these patients face progressive ventricular dysfunction and rising heart failure risk.
HFpEF patients
HFpEF patients are a large, underserved segment: heart failure affects about 6.7 million U.S. adults, and HFpEF accounts for roughly half of cases. TN-301 targets this indication with a disease-modifying aim, not just symptom relief, which matters because approved HFpEF options remain limited and outcomes are still poor.
- Large, growing HF segment
- Limited targeted therapies
- Disease-modifying positioning
Post-MI heart failure patients
Tenaya Therapeutics, Inc. targets post-MI heart failure patients who have lost cardiomyocytes after a myocardial infarction. In the U.S., about 805,000 heart attacks happen each year, and roughly 6.7 million adults live with heart failure, so the need for regenerative therapy is large.
The Reprogramming program aims to restore heart function by replacing lost muscle cells, a clear fit for this segment. These patients are high-need, high-risk, and often have limited recovery options after infarction.
- Post-MI patients lose cardiomyocytes
- Heart failure risk stays high
- Goal: restore pump function
Tenaya Targets Rare Mutations and Massive Heart Failure Markets
Tenaya Therapeutics, Inc. is focused on rare, genetically confirmed cardiomyopathy groups and large heart failure pools, including gHCM, gARVC, gDCM, HFpEF, and post-MI heart failure. The core logic is simple: small mutation-defined segments like MYBPC3 and PKP2 patients need precision therapies, while HFpEF and post-MI patients offer much larger addressable populations.
| Segment | Key size | Why it fits |
|---|---|---|
| gHCM | 1 in 500 adults | MYBPC3-defined, high unmet need |
| HFpEF | ~3.35M U.S. adults | Large, underserved |
Cost Structure
R and D payroll
R and D payroll is one of Tenaya Therapeutics, Inc. biggest cost lines, because scientific, clinical, and regulatory staff carry discovery through development. In biotech, specialized talent is the product engine, and payroll is tied directly to pipeline progress and trial execution.
Preclinical research spend
Tenaya Therapeutics, Inc. spends heavily on preclinical work because each gene therapy program needs animal studies, assay work, and translational tests before human trials start. As a clinical-stage company with no approved products, these upfront costs sit in R&D and are a key cash use before any clinical spend.
Clinical trial costs
Clinical trial costs are usually Tenaya Therapeutics, Inc.’s biggest development expense: site payments, monitoring, imaging, labs, and data management all add up fast. In rare-disease studies, multi-site logistics can push per-patient costs sharply higher, and trials often consume more than half of total R&D spend.
CMC and GMP manufacturing
CMC and GMP work is one of Tenaya Therapeutics, Inc.’s highest-cost build steps because AAV production, small-molecule supply, and release testing all sit inside tightly controlled cGMP runs. Quality is not optional: failed specs can block FDA review, and outsourced GMP adds vendor fees on top of batch costs.
- AAV batches are expensive to make
- Release tests slow and raise cost
- Outsourcing adds vendor margin
G and A and compliance
As a pre-revenue biotech, Tenaya Therapeutics still carries public-company overhead: legal, finance, insurance, investor relations, SEC reporting, and patent upkeep. These fixed costs hit before product sales, so G&A and compliance stay a real cash drain while the pipeline is still in development.
- Legal, finance, IR overhead
- Regulatory and IP maintenance
These costs are unavoidable until commercialization.
Tenaya’s Burn Is Driven by R&D, Trials, and GMP
Tenaya Therapeutics, Inc. cost structure is dominated by R and D, with payroll, preclinical studies, clinical trials, and GMP manufacturing taking most cash before any product revenue. As a pre-revenue gene therapy Company Name, fixed G&A costs like legal, SEC reporting, insurance, and IP upkeep stay high until commercialization.
| Cost line | Why it is high |
|---|---|
| R and D | Talent, trials, preclinical work |
| CMC and GMP | AAV build, testing, release |
| G and A | Public-company overhead |
Revenue Streams
Equity financings
As a clinical-stage biotech, Tenaya Therapeutics relies on equity financings as a core near-term funding source, with share issuances helping pay for research and development and other operating needs. This model matters because drug development cash burn stays high before product revenue starts.
In 2025, that means equity capital remains the main bridge between pipeline progress and longer-term value creation, especially while the Company is still pre-commercial.
Collaboration payments
Collaboration payments can bring upfront fees and research support, which helps Tenaya Therapeutics, Inc. offset costly R&D. In 2025, biotech platform deals still often used cash-heavy starts, and a single partner payment can fund key preclinical work without diluting shareholders.
Milestone receipts
Tenaya Therapeutics, Inc. can earn milestone receipts from development, regulatory, or commercial events, so the cash is variable and tied to partner progress or program wins. As of March 31, 2025, the Company reported $189.5 million in cash, cash equivalents, and marketable securities, so these payments would add non-dilutive funding if achieved.
Future product sales
Future product sales are still pre-commercial for Tenaya Therapeutics, so this revenue stream is not active yet and would start only after FDA approval. If its lead gene therapy candidates reach market, sales would likely come from rare cardiology and heart failure niches, which are small, high-unmet-need markets with limited approved treatment options.
- No product sales today
- Revenue starts after approval
- Targets rare heart disease
Royalties and licensing
Tenaya Therapeutics, Inc. can earn royalties if out-licensed assets reach net sales, and licensing can also turn platform IP into cash without building a full commercial force. In the latest filed FY2024 results, Tenaya reported $0.0 million revenue, so this stream is still standard biotech optionality, not a current cash driver.
- Royalties come from net sales
- Licensing monetizes IP and platform tech
- FY2024 revenue: $0.0 million
Tenaya Remains Pre-Commercial With $189.5M in Cash and No FY2024 Revenue
Tenaya Therapeutics, Inc. has no product sales yet; revenue is still mainly potential collaboration cash, milestones, and future royalties. As of March 31, 2025, it held $189.5 million in cash, cash equivalents, and marketable securities, while FY2024 revenue was $0.0 million.
| Stream | 2025 status | Data |
|---|---|---|
| Product sales | Pre-commercial | Not active |
| Cash balance | Liquidity | $189.5M |
| FY2024 revenue | No sales | $0.0M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.